Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche’s Tarceva ‘extends progression free survival’

Roche’s Tarceva ‘extends progression free survival’

3rd February 2009

Roche’s Tarceva increases the time patients with advanced lung cancer live before their condition deteriorates, according to a study.

The phase III trial – named Atlas – found the drug, when used in combination with Avastin (bevacizumab), extended the progression free survival, in comparison to Avastin and placebo.

It also noted the adverse events when the therapies were used together were consistent with previous studies and no new safety signals were observed.

Commenting on the study, William Burns, chief executive officer of Roche’s pharmaceuticals division said: “Atlas is the second study to show that people with lung cancer who took the daily pill Tarceva following initial treatment lived longer without their cancer getting worse.”

Both Avastin and Tarceva are available for the treatment of lung cancer in Europe and the US.

Last month, Roche announced its MabThera had received positive opinion from the European Union’s Committee on Human Medicinal Products.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.